Drug Discovery Biotechnology Fierce Biotech Computational Chemistry Longevity Tech TechBio vs Biotech

Retrieved sources

[E1] Isomorphic Labs — https://www.isomorphiclabs.com/

yaml 
founded_year: "2021"
funding: Total funding USD 2,701,700,000; notable rounds include Seed (2022-04-01) USD 1.7M, Seed (2023-09-01), Corporate round (2021-11-01), Venture (2025-03-01) USD 600.0M, Series B (2026-05-01) USD 2.1B
name: Isomorphic Labs
headquarters:
  address: London, GB
  city: London
  country: United Kingdom
workforce:
  total: 447
financials:
  revenueAnnual: 155500000
  fundingTotal: 2701700000
  fundingLatestRound:
    name: Series b
    date: 2026-05-01
    amount: 2100000000

Value Proposition & Features

Isomorphic Labs is a London-based biotechnology research company developing AI systems for drug design and discovery, with the goal of accelerating medicine development and improving human health. [E1] It describes its model as developing AI models, generating biological data, discovering new biology, and advancing potential medicines toward clinical testing. [c1h9v5]
Priority features:
  • Unified AI drug-design engine: IsoDDE is intended to integrate molecular-structure prediction, biological-activity modeling, and candidate design in one system. [8qn6yd]
  • Protein–ligand prediction: Isomorphic reports improved prediction of protein and small-molecule binding structures compared with AlphaFold 3. [89hsw4]
  • Antibody–antigen modeling: The company reports higher antibody–antigen structure-prediction accuracy than AlphaFold 3. [89hsw4]
  • Binding-affinity estimation: IsoDDE estimates how strongly drug candidates bind biological targets without requiring experimental crystal structures. [89hsw4]
  • AI-generated biological data: The company combines models with internally generated data and new biological measurements. [c1h9v5] [4e5jcd]
  • Internal drug development: Isomorphic plans to use its models both with pharmaceutical partners and for medicines developed in-house. [7peqmx]
  • Therapeutic-program development: Its stated objective is to move AI-designed candidates toward clinical trials. [tnxmj7]
  • Research partnerships: The company has announced collaborations with Eli Lilly and Novartis. [7peqmx]

Product Roadmap / Announcements

As of October 8, 2026,
  • October 7, 2026: Isomorphic Labs joined the Virtual Biology Initiative , a Biohub-convened effort involving funding, data, computation, and biological-measurement technologies to generate AI-ready biological data. [4e5jcd]
  • September 29, 2026: The company published an account of its integrated approach to medicine development, spanning AI-model development, data generation, biological discovery, and clinical translation. [c1h9v5]
  • February 2026: Isomorphic published technical claims about IsoDDE’s performance in protein–ligand and antibody–antigen structure prediction and binding-affinity estimation. [89hsw4] [8qc5zn]
  • End of 2026: The company is reported to be targeting initiation of its first clinical trials by the end of 2026. [tnxmj7]

Recent Developments

Within the past 90 days, Isomorphic Labs joined the Virtual Biology Initiative and described a strategy to move from AI models and biological data through drug discovery and clinical development. [c1h9v5] [4e5jcd] The company is also reported to be in early discussions about a potential financing at a valuation of at least $40 billion, although the financing had not closed and terms could change. [7peqmx]

History and Origin Story

Isomorphic Labs was founded in 2021 as a spinout from Alphabet’s Google DeepMind, with the mission of applying DeepMind’s AlphaFold -related advances to drug discovery. [7peqmx] Its key inflection points include a reported $600 million financing in 2025, the development and publication of IsoDDE results in February 2026, and a $2.1 billion Series B in May 2026. [8qc5zn] [7nzlcn]

Fundraising History

Round Date Amount Lead investor
Corporate round November 2021 Undisclosed Alphabet
Seed April 2022 $1.7M Not disclosed
Seed September 2023 Undisclosed Not disclosed
Venture March 2025 $600M Not disclosed
Series B May 2026 $2.1B Thrive Capital
Total — $2.7017B reported —
Sources for Table: [7nzlcn]
The retrieved company metadata reports total funding of approximately $2.7017 billion. [E1]
Alphabet CapitalG GV MGX Temasek Thrive Capital UK Sovereign AI Fund [7nzlcn]

Notable Team Members

Demis Hassabis is associated with Isomorphic Labs through his leadership of Google DeepMind and the company’s origin as a DeepMind spinout. [7peqmx] The retrieved results do not provide a sufficiently authoritative, current leadership roster for additional named executives.

Market Sizing

Category, Market Size, and Category Growth

Isomorphic Labs operates in AI-enabled drug discovery , at the intersection of biotechnology, computational biology, and pharmaceutical research. Its commercial opportunity is tied to applying AI to reduce the time and cost of drug discovery and development. [83rnsp]
Isomorphic Labs appears to operate through research collaborations, proprietary internal development, and pharmaceutical partnerships rather than a publicly documented self-serve software-pricing model. [7peqmx]

Revenue Trajectory Estimates

The retrieved company metadata reports annual revenue of $155.5 million, but it does not explain whether this figure represents recognized revenue, partnership payments, licensing income, or another estimate. [E1]

Competitive Landscape

Who it's for, who it's not for

Isomorphic Labs is aimed at pharmaceutical companies, biotechnology researchers, and internal drug-development programs that need computational support for target biology, molecular design, candidate selection, and therapeutic development. Its announced collaborations with Eli Lilly and Novartis indicate a focus on large-scale pharmaceutical research partnerships. [7peqmx]
It is not positioned in the retrieved sources as a general-purpose AI tool, a consumer health application, or a publicly accessible drug-design SaaS product; its models are described as internal and its work as partnership-based or in-house. [apnoa9]

Viable Alternatives

  • Insitro : AI-native drug-discovery and development company cited among Isomorphic Labs’ private competitors. [tnxmj7]
  • Enveda Biosciences : Computational and AI-oriented drug-discovery company listed as a competitor. [tnxmj7]
  • Anew Labs : Private AI-biotechnology competitor identified in market coverage. [tnxmj7]
  • OpenAI : Technology-company alternative entering life-sciences research with a dedicated model, according to reported coverage. [7peqmx]
  • Large pharmaceutical R&D organizations: Eli Lilly and Johnson & Johnson are cited as competing organizations with substantial internal drug-discovery capabilities. [tnxmj7]

Competitor Table

Competitor Description
Insitro AI-native drug-discovery and development company cited as a private competitor.
Enveda Biosciences Enveda Biosciences Biotechnology company using computational methods in drug discovery.
Anew Labs Anew Labs Private company identified among Isomorphic Labs’ AI-drug-discovery competitors.
OpenAI General AI company reported to have released a model for life-sciences research.
Eli Lilly Eli Lilly Pharmaceutical company that is both an announced Isomorphic Labs partner and a large-scale drug-development alternative.
Sources for Table: [tnxmj7] [7peqmx]

Sources

Sources (retrieved)

[E1] Exa.ai API response for data on Isomorphic Labs